These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 26604087)

  • 1. Liver transplantation for aHUS: still needed in the eculizumab era?
    Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
    Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.
    Tran H; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Nephrol; 2014 Mar; 29(3):477-80. PubMed ID: 24221349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
    Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C; Verhave JC; Berger SP; van de Kar NCAJ; Wetzels JFM
    Am J Kidney Dis; 2017 Dec; 70(6):770-777. PubMed ID: 28821363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of atypical hemolytic uremic syndrome in a second renal transplant.
    Zwang NA; Ho B; Kanwar YS; Lewis B; Cusick M; Friedewald JJ; Gallon L
    J Nephrol; 2018 Feb; 31(1):165-172. PubMed ID: 28224376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience.
    Kant S; Bhalla A; Alasfar S; Alachkar N
    BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics and outcome of atypical hemolytic-uremic syndrome in Turkish children: a retrospective study between 2010 and 2017, a single-center experience.
    Conkar S; Mir S; Berdeli A
    Iran J Kidney Dis; 2019 Sep; 13(5):316-321. PubMed ID: 31705748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable long-term outcomes of isolated liver transplantation in a child with atypical hemolytic uremic syndrome caused by a novel complement factor H mutation
.
    Cho H; Lee Y
    Clin Nephrol; 2017 Jul; 88(1):52-56. PubMed ID: 28502324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation in pediatric aHUS within the era of eculizumab therapy.
    Özçakar ZB; Ozaltin F; Gülhan B; Çomak E; Parmaksız G; Baskın E; Topaloğlu R; Kasap Demir B; Canpolat N; Yuruk Yildirim Z; Demircioğlu Kılıç B; Yüksel S; Söylemezoğlu O
    Pediatr Transplant; 2021 May; 25(3):e13914. PubMed ID: 33217100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
    Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
    Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation.
    Okumi M; Tanabe K
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():9-13. PubMed ID: 26988663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome.
    González CC; López-Jiménez V; Vázquez-Sánchez T; Vázquez-Sánchez E; Cabello M; Hernández-Marrero D
    Transplant Proc; 2022; 54(1):25-26. PubMed ID: 34906374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.
    Bamhraz AA; Rahim KA; Faqeehi HY; Alanazi A
    Kidney Blood Press Res; 2020; 45(6):939-954. PubMed ID: 33238263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome.
    Zuber J; Frimat M; Caillard S; Kamar N; Gatault P; Petitprez F; Couzi L; Jourde-Chiche N; Chatelet V; Gaisne R; Bertrand D; Bamoulid J; Louis M; Sberro Soussan R; Navarro D; Westeel PF; Frimat L; Colosio C; Thierry A; Rivalan J; Albano L; Arzouk N; Cornec-Le Gall E; Claisse G; Elias M; El Karoui K; Chauvet S; Coindre JP; Rerolle JP; Tricot L; Sayegh J; Garrouste C; Charasse C; Delmas Y; Massy Z; Hourmant M; Servais A; Loirat C; Fakhouri F; Pouteil-Noble C; Peraldi MN; Legendre C; Rondeau E; Le Quintrec M; Frémeaux-Bacchi V
    J Am Soc Nephrol; 2019 Dec; 30(12):2449-2463. PubMed ID: 31575699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international consensus approach to the management of atypical hemolytic uremic syndrome in children.
    Loirat C; Fakhouri F; Ariceta G; Besbas N; Bitzan M; Bjerre A; Coppo R; Emma F; Johnson S; Karpman D; Landau D; Langman CB; Lapeyraque AL; Licht C; Nester C; Pecoraro C; Riedl M; van de Kar NC; Van de Walle J; Vivarelli M; Frémeaux-Bacchi V;
    Pediatr Nephrol; 2016 Jan; 31(1):15-39. PubMed ID: 25859752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
    Ranch D; Crowther B; Arar M; Assanasen C
    Pediatr Transplant; 2014 Sep; 18(6):E185-9. PubMed ID: 24931815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical hemolytic uremic syndrome recurrence after kidney transplantation.
    Matar D; Naqvi F; Racusen LC; Carter-Monroe N; Montgomery RA; Alachkar N
    Transplantation; 2014 Dec; 98(11):1205-12. PubMed ID: 24933457
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.